Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Histogenics
830 Winter Street, 3rd Floor
Waltham, MA 2451
Phone: 781-547-7900
www.histogenics.com

Histogenics is a leading regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration. In May of 2011, Histogenics acquired Israeli cell-therapy company ProChon BioTech. Histogenics' flagship products focus on the treatment of active patients suffering from articular cartilage derived pain and immobility. The Company takes an interdisciplinary approach to engineering neocartilage that looks, acts and lasts like hyaline cartilage. It is developing new treatments for sports injuries and other orthopedic conditions, where demand is growing for long-term alternatives to joint replacement. Histogenics has successfully completed Phase 1 and Phase 2 clinical trials in which the NeoCart autologous tissue implant's effectiveness is compared to that of standard microfracture surgery.

Key Contact
Name
Patrick O'Donnell
Title
CEO
Funding Events

Date
Amount
Type
Investors
Valuation
07/24/12 $49,000,000 Altima Partners
BioMed Ventures
Boston Millennia Partners
FinTech GIMV Fund
Flare Capital Partners
Inflection Point Capital
ProChon Holdings
Sofinnova Ventures
Split Rock Partners
undisclosed


Featured Reading